📈 Live Market Tracking
Every NSE and BSE corporate filing, read and explained by AI within minutes — impact, key figures, short/long-term view and what to watch.
Live · AI analyzer runs every 5 min (07:00–23:55 IST)
0 analysed today
FollowTelegram
0
Today
152,139
All-time analysed
43,645
Positive
6,747
Negative
92,898
Neutral
8,781
Watch
📊 Last 7 days — analysed filings by sentiment
Note: These are AI-generated, educational summaries of public NSE
filings — grounded in each document, but not investment advice and possibly incomplete.
Verify against the original filing and consult a SEBI-registered adviser before acting.
131 announcements match the current filters (relevance ≥ 5).
GPPL Recommends Final Dividend of ₹5.00 per Share; FY26 Net Profit Jumps 25% YoY
Gujarat Pipavav Port Limited (GPPL) has recommended a final dividend of ₹5.00 per equity share for FY26, reflecting a strong cash position. The company reported a robust financial performance with annual revenue from operations growing 17.5% to ₹11,583.78 million. Net profit for the full year increased significantly by 25.3% to ₹5,003.55 million compared to ₹3,991.60 million in the previous year. The dividend is subject to shareholder approval at the AGM scheduled for September 9, 2026.
Key Highlights
Recommended a final dividend of ₹5.00 per equity share for the financial year 2025-26
Annual revenue from operations rose to ₹11,583.78 million from ₹9,860.43 million in FY25
Net profit for FY26 stood at ₹5,003.55 million, up 25.3% from ₹3,991.60 million YoY
Earnings Per Share (EPS) for the full year improved to ₹10.35 compared to ₹8.26 in FY25
Proposed a final settlement of ₹188.31 million with Gujarat Maritime Board regarding bank guarantee invocation
👀 What to Watch
Investors should consider the healthy dividend payout and strong double-digit profit growth as a sign of operational strength. The stock remains attractive for those seeking a combination of yield and steady infrastructure-linked growth.
Aditya Infotech (CPPLUS) Approves ₹1.64 Dividend and USD 400k Taiwan Subsidiary Investment
Aditya Infotech Limited (CPPLUS) has announced its FY26 financial results and recommended a final dividend of ₹1.64 per equity share, representing 164% of the face value. The company is also expanding its global footprint by investing up to USD 400,000 in its wholly-owned Taiwan subsidiary. For the fiscal year ended March 31, 2026, the company's audited subsidiaries contributed ₹21,607.12 million in revenue and ₹291.66 million in net profit. These developments reflect a balanced approach between rewarding shareholders and pursuing international growth.
Key Highlights
Recommended a final dividend of ₹1.64 per equity share (164% of face value) for FY26.
Approved further investment of up to USD 400,000 in wholly-owned subsidiary Aditya Infotech Taiwan Co. Ltd.
Audited subsidiaries reported total revenues of ₹21,607.12 million for the year ended March 31, 2026.
Net profit after tax for audited subsidiaries stood at ₹291.66 million for the same period.
Total assets of the audited subsidiaries were valued at ₹15,027.02 million as of March 31, 2026.
👀 What to Watch
Investors should take note of the healthy dividend payout and the strategic investment in Taiwan, which could strengthen the company's supply chain and global presence. Monitor the full financial results for margin performance and growth outlook.
Aditya Infotech Recommends ₹1.64 Final Dividend and Approves USD 400k Subsidiary Investment
Aditya Infotech Limited (CPPLUS) has recommended a final dividend of ₹1.64 per share (164% of face value) for FY26, pending shareholder approval at the upcoming AGM. The company reported consolidated annual revenues of ₹21,607.12 million and a net profit of ₹291.66 million for the financial year ended March 31, 2026. Furthermore, the board approved an additional investment of up to USD 400,000 in its wholly-owned subsidiary in Taiwan to strengthen its international presence. The dividend, once approved, is slated for payment within 30 days of the AGM conclusion.
Key Highlights
Recommended a final dividend of ₹1.64 per equity share, representing 164% of the ₹1 face value.
Reported consolidated annual revenue of ₹21,607.12 million for the financial year ended March 31, 2026.
Achieved a consolidated net profit after tax of ₹291.66 million for FY 2025-26.
Approved a capital infusion of up to USD 400,000 into the wholly-owned subsidiary, Aditya Infotech Taiwan Co. Ltd.
Statutory auditors Walker Chandiok & Co LLP issued an unmodified opinion on the annual financial results.
👀 What to Watch
Investors should monitor the record date for the ₹1.64 dividend to ensure eligibility and keep an eye on the growth of the Taiwan subsidiary as a potential driver for future international revenue.
Aditya Infotech (CPPLUS) FY26 PAT Jumps 166% to ₹368 Cr; Upgrades FY27 Revenue Target to ₹6,500 Cr
Aditya Infotech Limited (CPPLUS) delivered a robust financial performance for FY26, with revenue growing 35.6% YoY to ₹4,221 crore and adjusted PAT surging 166.1% to ₹368 crore. The company successfully expanded its EBITDA margins from 8.3% to 13.7% through backward integration and strategic price hikes. Management has significantly upgraded its FY27 revenue guidance to ₹6,000–6,500 crore, reflecting confidence in volume growth and its transition toward AI-enabled surveillance solutions. Strategic partnerships with L&T Semiconductor and Qualcomm are set to bolster their R&D and localization efforts.
Key Highlights
FY26 Consolidated Revenue reached ₹4,221 Cr, up 35.6% YoY, with Q4 revenue alone growing 45.5% to ₹1,422 Cr.
Adjusted PAT for the full year stood at ₹368 Cr, representing a massive 166.1% growth over FY25.
Upgraded FY27 revenue guidance to ₹6,000–6,500 Cr from the earlier estimate of ₹5,350-5,550 Cr.
EBITDA margins improved significantly to 13.7% in FY26 compared to 8.3% in the previous fiscal year.
Manufacturing capacity at the Kadapa plant has reached 2.5 million units per month with plans to double capacity by FY28.
👀 What to Watch
Investors should take note of the significant margin expansion and the aggressive upward revision in revenue guidance for FY27. The company's focus on backward integration and high-value AI solutions positions it well for long-term growth, though monitoring the impact of global semiconductor price volatility remains essential.
Aditya Infotech Q4 PAT Surges 207% to ₹169 Cr; FY27 Revenue Guidance Raised to ₹6,500 Cr
Aditya Infotech (CPPLUS) delivered a stellar Q4 FY26 performance with revenue growing 45.5% YoY to ₹1,422 crore and adjusted PAT jumping 207.7% to ₹169.1 crore. EBITDA margins expanded significantly by 808 bps to 18.1% in Q4, driven by a favorable product mix where IP products now account for 79% of the CP PLUS portfolio. The company maintains a dominant 45.4% market share in India's surveillance industry and has declared a dividend of ₹1.60 per share. Management issued strong FY27 guidance, targeting revenue up to ₹6,500 crore and EBITDA margins of 14%-15%.
Key Highlights
Q4 FY26 Revenue increased 45.5% YoY to ₹1,422.0 crore, while Full Year FY26 Revenue rose 35.6% to ₹4,220.8 crore.
Q4 EBITDA margins expanded by 808 bps YoY to 18.1%, with EBITDA growing 162.4% to ₹258.3 crore.
Adjusted PAT for FY26 stood at ₹368.0 crore, a growth of 166.1% YoY, reflecting strong operational leverage.
CP PLUS brand market share reached 45.4% in Q3 FY26, supported by a manufacturing capacity of 2.5 million units per month.
Management provided robust FY27 guidance with revenue expected between ₹6,000–6,500 crore and PAT margins of 8.5%–9.5%.
👀 What to Watch
Investors should consider this a strong growth story given the massive margin expansion and dominant market share in a consolidating industry. The upward revision of FY27 guidance and aggressive backward integration into lens and cable manufacturing provide high earnings visibility.
Aditya Infotech (CPPLUS) Declares ₹1.64 Dividend and USD 400k Taiwan Investment
Aditya Infotech Limited (CPPLUS) has approved its audited financial results for the fiscal year ended March 31, 2026. The Board recommended a final dividend of ₹1.64 per share, representing 164% of the face value. Furthermore, the company is strengthening its global presence by investing up to USD 400,000 in its wholly owned subsidiary, Aditya Infotech Taiwan Co. Ltd. The audit report highlights that three key subsidiaries alone contributed ₹21,607.12 million to the group's revenue.
Key Highlights
Recommended a final dividend of ₹1.64 per equity share (164% of face value of ₹1).
Approved additional investment up to USD 400,000 in Aditya Infotech Taiwan Co. Ltd.
Three subsidiaries reported a combined revenue of ₹21,607.12 million for FY26.
Net profit after tax for the three subsidiaries stood at ₹291.66 million.
Statutory auditors issued an unmodified opinion on the consolidated financial results.
👀 What to Watch
Investors should monitor the upcoming AGM for dividend approval and track the impact of the Taiwan investment on the company's R&D and supply chain capabilities.
Aditya Infotech: Atul B. Lall Resigns as Dixon Technologies Stake Drops to 2.38%
Mr. Atul B. Lall has resigned as a Non-Executive Non-Independent Director of Aditya Infotech Limited (CPPLUS) effective May 25, 2026. The resignation is a direct result of Dixon Technologies (India) Limited (DTIL) losing its board nomination rights after selling 44,95,880 equity shares. DTIL's shareholding in the company has decreased from 6.20% to 2.38%, falling below the 4% threshold required to maintain a board seat. This change reflects a significant reduction in the equity stake held by a key strategic partner.
Key Highlights
Atul B. Lall resigned as Non-Executive Non-Independent Director effective May 25, 2026.
Dixon Technologies (DTIL) sold 44,95,880 shares on February 25, 2026, reducing its stake from 6.20% to 2.38%.
DTIL lost its board nomination rights as its holding fell below the 4% threshold mandated by Article 102A.
The resignation was formally noted by the Nomination & Remuneration Committee on May 25, 2026.
👀 What to Watch
Investors should monitor if the reduction in Dixon Technologies' stake signals a change in the operational or manufacturing partnership between the two companies. The loss of a board representative from a major industry player like Dixon warrants a closer look at future strategic alignments.
Piramal Pharma Receives US FDA EIR for Digwal Facility, Inspection Successfully Closed
Piramal Pharma Limited has announced the successful closure of a US FDA inspection at its manufacturing facility in Digwal, Telangana. The company received an Establishment Inspection Report (EIR) on May 18, 2026, following an inspection that was first reported in February 2026. This regulatory clearance confirms that the facility meets the required standards for products destined for the US market. The resolution of this inspection removes a significant regulatory overhang for the company's manufacturing operations.
Key Highlights
US FDA issued an Establishment Inspection Report (EIR) for the Digwal, Telangana facility
The inspection, which commenced in February 2026, is now officially concluded and closed
Successful closure indicates compliance with stringent US manufacturing and quality standards
The Digwal plant is a critical site for Piramal Pharma's global supply chain and API production
👀 What to Watch
This is a positive development that de-risks the company's US revenue stream; investors should maintain their positions as regulatory compliance is a key valuation driver for Indian pharma.
Piramal Pharma's Sellersville Facility Receives US FDA Form-483 with 3 VAI Observations
Piramal Pharma Limited's Sellersville facility in the USA underwent a US FDA Good Manufacturing Practices (GMP) inspection from May 4 to May 8, 2026. The inspection concluded with the issuance of a Form-483 containing three observations. Significantly, the inspectors recommended a classification of Voluntary Action Indicated (VAI), which suggests the issues are not critical. The company confirmed that none of the observations pertain to data integrity and is preparing a formal response to the agency.
Key Highlights
US FDA inspection conducted at the Sellersville (USA) facility from May 4 to May 8, 2026
Form-483 issued with 3 specific observations at the conclusion of the audit
Inspectors recommended a classification of Voluntary Action Indicated (VAI)
Zero observations reported related to data integrity issues
Company is preparing a detailed response to be submitted within stipulated timelines
👀 What to Watch
Investors should monitor for the final Establishment Inspection Report (EIR) to confirm the VAI status. While Form-483s are common, the lack of data integrity issues and the VAI recommendation mitigate significant regulatory risk.
CRISIL Assigns 'A/Stable' Rating to CPPLUS Subsidiary's Rs 325 Cr Bank Facilities
CRISIL Ratings has assigned a long-term rating of 'CRISIL A/Stable' and a short-term rating of 'CRISIL A1' to the bank loan facilities of AIL Dixon Technologies Private Limited. This entity is a material wholly-owned subsidiary of Aditya Infotech Limited (CPPLUS). The total bank loan facilities covered under this rating amount to Rs. 325 Crore. This assignment provides a benchmark for the subsidiary's creditworthiness and its ability to service debt obligations efficiently.
Key Highlights
CRISIL assigned a long-term rating of 'CRISIL A/Stable' for bank facilities.
CRISIL assigned a short-term rating of 'CRISIL A1' for bank facilities.
Total bank loan facilities rated amount to Rs. 325 Crore.
Ratings assigned to AIL Dixon Technologies Private Limited, a material wholly-owned subsidiary.
👀 What to Watch
Investors should take this as a positive sign of the subsidiary's financial stability and the group's ability to leverage its balance sheet for growth. No immediate action is required, but the 'Stable' outlook suggests consistent performance is expected.
Piramal Pharma Approves FY26 Results; Re-appoints Chairperson & CEO for 3-Year Terms
Piramal Pharma's Board has approved the audited financial results for the quarter and full year ended March 31, 2026, with an unmodified audit opinion. The company confirmed the re-appointment of Ms. Nandini Piramal as Chairperson and Mr. Peter DeYoung as Executive Director for three-year terms starting in 2027 and 2026 respectively. Additionally, two independent directors were re-appointed for five-year terms, and Mr. Maneesh Sharma was appointed as the new Company Secretary. The company also announced a change in its registered office address effective April 30, 2026.
Key Highlights
Approved audited standalone and consolidated financial results for the fiscal year ended March 31, 2026.
Re-appointed Nandini Piramal as Chairperson for a 3-year term effective April 1, 2027.
Re-appointed Peter DeYoung as Executive Director for a 3-year term effective October 6, 2026.
Appointed Maneesh Sharma as Company Secretary and Compliance Officer effective April 29, 2026.
Registered office address to change to Ananta Building, Piramal Corporate Park, effective April 30, 2026.
👀 What to Watch
Investors should monitor the detailed FY26 financial statements for growth metrics and margin improvements. The continuity in top leadership is a positive sign for the company's long-term strategic stability.
Piramal Pharma Approves FY26 Results; Re-appoints Nandini Piramal as Chairperson for 3 Years
Piramal Pharma's Board has approved the audited financial results for FY26 with an unmodified auditor's opinion. Key leadership continuity was secured through the re-appointment of Ms. Nandini Piramal as Chairperson and Mr. Peter DeYoung as Executive Director for three-year terms. The board also re-appointed two Independent Directors for five-year terms and appointed a new Company Secretary. These moves ensure stability in governance and strategic oversight for the upcoming years.
Key Highlights
Audited FY26 financial results approved with an unmodified opinion from Statutory Auditors.
Nandini Piramal re-appointed as Chairperson for 3 years starting April 1, 2027.
Peter DeYoung re-appointed as Executive Director for 3 years starting October 6, 2026.
Maneesh Sharma appointed as Company Secretary and Compliance Officer effective April 29, 2026.
Registered office address changed within Mumbai effective April 30, 2026.
👀 What to Watch
Investors should maintain their positions as leadership continuity provides stability. Focus on the specific FY26 profit and revenue growth figures in the detailed report to assess fundamental performance.
Piramal Pharma Re-appoints Nandini Piramal & Peter DeYoung; Appoints New Company Secretary
Piramal Pharma's Board has approved the re-appointment of Chairperson Nandini Piramal and Executive Director Peter DeYoung for three-year terms starting in 2027 and 2026, respectively. The company also appointed Maneesh Sharma as the permanent Company Secretary and Compliance Officer, effective April 29, 2026, replacing the interim officer. Additionally, the Board cleared the audited financial results for FY26 with an unmodified audit opinion from Suresh Surana & Associates LLP. Two independent directors were also re-appointed for five-year terms to ensure governance continuity.
Key Highlights
Nandini Piramal re-appointed as Chairperson for a 3-year term effective April 1, 2027
Peter DeYoung re-appointed as Executive Director for a 3-year term effective October 6, 2026
Maneesh Sharma appointed as Company Secretary and Compliance Officer effective April 29, 2026
Audited FY26 financial results approved with an unmodified opinion from statutory auditors
Registered office address to change within Mumbai effective April 30, 2026
👀 What to Watch
Investors should view these re-appointments as a sign of leadership stability and strategic continuity. No immediate action is required as the administrative and leadership changes are part of routine corporate governance.
Piramal Pharma Approves FY26 Results, Re-appoints Leadership and Names New Company Secretary
Piramal Pharma's Board has approved the audited financial results for the fiscal year ended March 31, 2026, with an unmodified audit opinion. The company confirmed the re-appointment of Chairperson Nandini Piramal and CEO Peter DeYoung for three-year terms starting in 2027 and 2026 respectively. Additionally, Maneesh Sharma has been appointed as the new Company Secretary and Compliance Officer effective April 29, 2026. The board also approved the re-appointment of two Independent Directors for five-year terms and a change in the registered office address.
Key Highlights
Approved audited standalone and consolidated financial results for the full year ended March 31, 2026.
Re-appointed Ms. Nandini Piramal as Chairperson for a 3-year term effective April 1, 2027.
Re-appointed Mr. Peter DeYoung as Executive Director for a 3-year term effective October 6, 2026.
Appointed Mr. Maneesh Sharma as Company Secretary & Compliance Officer effective April 29, 2026.
Re-appointed Independent Directors Sridhar Gorthi and Peter Stevenson for 5-year terms starting March 2027.
👀 What to Watch
Investors should monitor the detailed FY26 financial performance metrics once published to evaluate the company's growth trajectory. The continuity in top leadership provides stability for the firm's long-term strategic execution.
Piramal Pharma Q4FY26: Revenue Flat at ₹2,752 Cr, FY26 EBITDA Drops 28% Amid Impairment Loss
Piramal Pharma reported flat Q4FY26 revenue of ₹2,752 Cr and a 3% decline in annual revenue to ₹8,869 Cr, primarily due to inventory destocking in the CDMO segment. The company recorded a consolidated net loss of ₹326 Cr for FY26, weighed down by a ₹176 Cr impairment charge on intangible assets under development. While the CDMO business struggled with a 10% annual revenue drop, the Consumer Healthcare division grew 17% with strong e-commerce traction. Management expects a recovery in FY27 driven by improved biopharma funding and new product acquisitions like Kenalog.
Key Highlights
FY26 EBITDA margins contracted to 13% from 17% in FY25, with absolute EBITDA falling 28% to ₹1,135 Cr.
Recognized a one-time impairment loss of ₹176 Cr in Q4FY26 due to reassessed commercial viability of certain intangible assets.
Consumer Healthcare (PCH) power brands grew 24% YoY, now contributing 52% of segment sales with e-commerce growing at 48%.
CDMO segment saw a 75% YoY increase in US biopharma funding in H2FY26, leading to a healthy pick-up in order inflows.
Net Debt remained stable at ₹4,140 Cr, while the company invested US$94Mn in Capex during FY26.
👀 What to Watch
Investors should monitor the recovery in the CDMO order book and margin improvement in FY27 as management expects a turnaround. The stock may face short-term pressure due to the significant annual loss and margin contraction.
Piramal Pharma Q4 FY26: Revenue Flat at ₹2,752 Cr, Reports Net Loss of ₹9 Cr on Impairment
Piramal Pharma reported flat revenue of ₹2,752 Cr for Q4 FY26, while full-year revenue declined 3% to ₹8,869 Cr due to inventory destocking and slower CDMO inflows. The company posted a net loss of ₹9 Cr in Q4 after a ₹176 Cr impairment charge on intangible assets, though PAT before exceptional items grew 9% to ₹167 Cr. While the CDMO segment struggled with a 4% revenue decline, the Consumer Healthcare (PCH) segment showed robust growth of 17%. Management remains optimistic for FY27, citing a recovery in biopharma funding and the recent Kenalog acquisition.
Key Highlights
Q4 FY26 EBITDA declined 16% YoY to ₹507 Cr with margins contracting to 18% from 22% in the previous year.
Recognized a significant one-time impairment loss of ₹176 Cr in Q4 related to intangible assets under development.
Consumer Healthcare (PCH) revenue grew 17% YoY in Q4, with e-commerce sales surging 48% during the full year.
CDMO segment revenue fell 4% in Q4 and 10% for FY26, impacted by slower early-stage order inflows in the first half.
Net debt remained stable at ₹4,140 Cr, with a total FY26 Capex investment of US$94 million.
👀 What to Watch
Investors should exercise caution due to the contraction in EBITDA margins and the decline in the core CDMO business. Monitor the recovery of order inflows in FY27 and the successful integration of the Kenalog brand before considering new positions.
Piramal Pharma Re-appoints Top Leadership and Approves FY26 Audited Financial Results
Piramal Pharma's Board has approved the audited financial results for the quarter and fiscal year ended March 31, 2026, with an unmodified audit opinion. The company ensured leadership stability by re-appointing Chairperson Nandini Piramal and CEO Peter DeYoung for three-year terms starting in 2027 and 2026, respectively. Additionally, Maneesh Sharma has been appointed as the new Company Secretary and Compliance Officer effective April 29, 2026. The board also extended the terms of two Independent Directors for five years each, starting in March 2027.
Key Highlights
Approved audited standalone and consolidated financial results for the full year ended March 31, 2026.
Re-appointed Ms. Nandini Piramal as Chairperson for a 3-year term effective April 1, 2027.
Re-appointed Mr. Peter DeYoung as Executive Director for a 3-year term effective October 6, 2026.
Appointed Mr. Maneesh Sharma as Company Secretary and KMP effective April 29, 2026, following the cessation of the interim officer.
Re-appointed Independent Directors Sridhar Gorthi and Peter Stevenson for second 5-year terms starting March 2027.
👀 What to Watch
Investors should take confidence in the leadership continuity and the clean audit report. Focus on the detailed financial performance metrics in the FY26 results to assess the company's growth trajectory.
Piramal Pharma Approves FY26 Results and Re-appoints Key Leadership for 3-5 Year Terms
Piramal Pharma's board has approved the audited financial results for the fiscal year ended March 31, 2026, with an unmodified audit opinion. The company ensured leadership stability by re-appointing Chairperson Nandini Piramal and Executive Director Peter DeYoung for three-year terms starting in 2027 and 2026, respectively. Furthermore, two independent directors were re-appointed for five-year terms, and a new Company Secretary was appointed. The board also authorized a change in the company's registered office address within Mumbai effective April 30, 2026.
Key Highlights
Approved audited standalone and consolidated financial results for FY26 with an unmodified auditor's opinion.
Re-appointed Ms. Nandini Piramal as Chairperson for a 3-year term effective April 1, 2027.
Re-appointed Mr. Peter DeYoung as Executive Director for a 3-year term effective October 6, 2026.
Extended terms for Independent Directors Sridhar Gorthi and Peter Stevenson for 5 years each starting March 2027.
Appointed Mr. Maneesh Sharma as Company Secretary and Compliance Officer effective April 29, 2026.
👀 What to Watch
Investors should review the detailed FY26 financial statements to assess the company's operational performance. The continuity in top management and the board is a positive sign for long-term strategic stability.
Piramal Pharma Approves FY26 Audited Results and Re-appoints Key Leadership
Piramal Pharma's board has approved the audited financial results for the fiscal year ended March 31, 2026, with auditors issuing an unmodified opinion. The company ensured leadership continuity by re-appointing Chairperson Nandini Piramal and CEO Peter DeYoung for additional 3-year terms. Additionally, two independent directors were re-appointed for 5-year terms, and Maneesh Sharma was named the new Company Secretary. The board also approved a change in the registered office address effective April 30, 2026.
Key Highlights
Approved audited standalone and consolidated financial results for the year ended March 31, 2026
Re-appointed Ms. Nandini Piramal as Chairperson for a 3-year term starting April 1, 2027
Re-appointed Mr. Peter DeYoung as Executive Director for a 3-year term starting October 6, 2026
Appointed Mr. Maneesh Sharma as Company Secretary and Compliance Officer effective April 29, 2026
Statutory auditors issued an unmodified opinion on the financial results for the period ended March 31, 2026
👀 What to Watch
Investors should review the detailed financial performance metrics for FY26 as leadership stability is now secured for the next three years. The unmodified audit opinion provides confidence in the reported financial integrity.
Aditya Infotech (CPPLUS) Signs 50:50 Joint Venture Agreement with Orient Cables
Aditya Infotech Limited (CPPLUS) has executed a definitive 50:50 Joint Venture agreement with Orient Cables (India) Limited to manufacture electric cables, including LAN and CCTV cables. This strategic move follows an earlier MoU signed in February 2026 and aims to facilitate backward integration for the company's security products. The JV company will be an associate of Aditya Infotech, with equal board representation and joint control over operations. This arrangement is expected to secure the supply chain, improve cost efficiencies, and enhance quality control for CPPLUS's core business.
Key Highlights
Execution of a 50:50 Joint Venture agreement with Orient Cables (India) Limited on April 16, 2026
Focus on manufacturing LAN cables, CCTV cables, connectors, and terminated assemblies
Strategic backward integration to ensure reliable supply and enhance operational effectiveness
JV Company will supply products to both Aditya Infotech and Orient Cables for further sale
Governance structure includes equal board representation and mutual approval for critical matters
👀 What to Watch
Investors should view this as a positive long-term strategic move for supply chain stability and potential margin improvement through backward integration. Monitor the timeline for the commencement of manufacturing operations at the JV facility.
